The global Lysosomal Storage Disorder Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淟ysosomal Storage Disorder Drugs Industry Forecast鈥 looks at past sales and reviews total world Lysosomal Storage Disorder Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Lysosomal Storage Disorder Drugs sales for 2024 through 2030. With Lysosomal Storage Disorder Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lysosomal Storage Disorder Drugs industry.
This Insight Report provides a comprehensive analysis of the global Lysosomal Storage Disorder Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lysosomal Storage Disorder Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥 unique position in an accelerating global Lysosomal Storage Disorder Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lysosomal Storage Disorder Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lysosomal Storage Disorder Drugs.
United States market for Lysosomal Storage Disorder Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Lysosomal Storage Disorder Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Lysosomal Storage Disorder Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Lysosomal Storage Disorder Drugs players cover Novartis, Johnson & Johnson, Teva Pharmaceutical, Merck & Co, AbbVie, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Lysosomal Storage Disorder Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Other
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis
Johnson & Johnson
Teva Pharmaceutical
Merck & Co
AbbVie
Pfizer
GlaxoSmithKline
Sanofi
Merck KGaA
Abbott
Boehringer Ingelheim International
Takeda Pharmaceutical
Amicus Therapeutics
Moderna
Biomarin
JCR Pharmaceutical
ISU ABXIS
Idorsia Pharmaceuticals
AVROBIO
Resverlogix
Chiesi Farmaceutici
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lysosomal Storage Disorder Drugs market?
What factors are driving Lysosomal Storage Disorder Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lysosomal Storage Disorder Drugs market opportunities vary by end market size?
How does Lysosomal Storage Disorder Drugs break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Lysosomal Storage Disorder Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Lysosomal Storage Disorder Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Lysosomal Storage Disorder Drugs by Country/Region, 2019, 2023 & 2030
2.2 Lysosomal Storage Disorder Drugs Segment by Type
2.2.1 Enzyme Replacement Therapy
2.2.2 Stem Cell Therapy
2.2.3 Substrate Reduction Therapy
2.2.4 Other
2.3 Lysosomal Storage Disorder Drugs Sales by Type
2.3.1 Global Lysosomal Storage Disorder Drugs Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Lysosomal Storage Disorder Drugs Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Lysosomal Storage Disorder Drugs Sale Price by Type (2019-2024)
2.4 Lysosomal Storage Disorder Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Lysosomal Storage Disorder Drugs Sales by Application
2.5.1 Global Lysosomal Storage Disorder Drugs Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Lysosomal Storage Disorder Drugs Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Lysosomal Storage Disorder Drugs Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Lysosomal Storage Disorder Drugs Breakdown Data by Company
3.1.1 Global Lysosomal Storage Disorder Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Lysosomal Storage Disorder Drugs Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Lysosomal Storage Disorder Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Lysosomal Storage Disorder Drugs Revenue by Company (2019-2024)
3.2.2 Global Lysosomal Storage Disorder Drugs Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Lysosomal Storage Disorder Drugs Sale Price by Company
3.4 Key Manufacturers Lysosomal Storage Disorder Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lysosomal Storage Disorder Drugs Product Location Distribution
3.4.2 Players Lysosomal Storage Disorder Drugs Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Lysosomal Storage Disorder Drugs by Geographic Region
4.1 World Historic Lysosomal Storage Disorder Drugs 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Lysosomal Storage Disorder Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Lysosomal Storage Disorder Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Lysosomal Storage Disorder Drugs 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Lysosomal Storage Disorder Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Lysosomal Storage Disorder Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Lysosomal Storage Disorder Drugs Sales Growth
4.4 APAC Lysosomal Storage Disorder Drugs Sales Growth
4.5 Europe Lysosomal Storage Disorder Drugs Sales Growth
4.6 Middle East & Africa Lysosomal Storage Disorder Drugs Sales Growth
5 Americas
5.1 Americas Lysosomal Storage Disorder Drugs Sales by Country
5.1.1 Americas Lysosomal Storage Disorder Drugs Sales by Country (2019-2024)
5.1.2 Americas Lysosomal Storage Disorder Drugs Revenue by Country (2019-2024)
5.2 Americas Lysosomal Storage Disorder Drugs Sales by Type (2019-2024)
5.3 Americas Lysosomal Storage Disorder Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lysosomal Storage Disorder Drugs Sales by Region
6.1.1 APAC Lysosomal Storage Disorder Drugs Sales by Region (2019-2024)
6.1.2 APAC Lysosomal Storage Disorder Drugs Revenue by Region (2019-2024)
6.2 APAC Lysosomal Storage Disorder Drugs Sales by Type (2019-2024)
6.3 APAC Lysosomal Storage Disorder Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lysosomal Storage Disorder Drugs by Country
7.1.1 Europe Lysosomal Storage Disorder Drugs Sales by Country (2019-2024)
7.1.2 Europe Lysosomal Storage Disorder Drugs Revenue by Country (2019-2024)
7.2 Europe Lysosomal Storage Disorder Drugs Sales by Type (2019-2024)
7.3 Europe Lysosomal Storage Disorder Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lysosomal Storage Disorder Drugs by Country
8.1.1 Middle East & Africa Lysosomal Storage Disorder Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Lysosomal Storage Disorder Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Lysosomal Storage Disorder Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Lysosomal Storage Disorder Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lysosomal Storage Disorder Drugs
10.3 Manufacturing Process Analysis of Lysosomal Storage Disorder Drugs
10.4 Industry Chain Structure of Lysosomal Storage Disorder Drugs
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lysosomal Storage Disorder Drugs Distributors
11.3 Lysosomal Storage Disorder Drugs Customer
12 World Forecast Review for Lysosomal Storage Disorder Drugs by Geographic Region
12.1 Global Lysosomal Storage Disorder Drugs 麻豆原创 Size Forecast by Region
12.1.1 Global Lysosomal Storage Disorder Drugs Forecast by Region (2025-2030)
12.1.2 Global Lysosomal Storage Disorder Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Lysosomal Storage Disorder Drugs Forecast by Type (2025-2030)
12.7 Global Lysosomal Storage Disorder Drugs Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.1.3 Novartis Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Teva Pharmaceutical
13.3.1 Teva Pharmaceutical Company Information
13.3.2 Teva Pharmaceutical Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.3.3 Teva Pharmaceutical Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Teva Pharmaceutical Main Business Overview
13.3.5 Teva Pharmaceutical Latest Developments
13.4 Merck & Co
13.4.1 Merck & Co Company Information
13.4.2 Merck & Co Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.4.3 Merck & Co Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck & Co Main Business Overview
13.4.5 Merck & Co Latest Developments
13.5 AbbVie
13.5.1 AbbVie Company Information
13.5.2 AbbVie Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.5.3 AbbVie Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 AbbVie Main Business Overview
13.5.5 AbbVie Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.6.3 Pfizer Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 GlaxoSmithKline
13.7.1 GlaxoSmithKline Company Information
13.7.2 GlaxoSmithKline Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.7.3 GlaxoSmithKline Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 GlaxoSmithKline Main Business Overview
13.7.5 GlaxoSmithKline Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.8.3 Sanofi Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Merck KGaA
13.9.1 Merck KGaA Company Information
13.9.2 Merck KGaA Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.9.3 Merck KGaA Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Merck KGaA Main Business Overview
13.9.5 Merck KGaA Latest Developments
13.10 Abbott
13.10.1 Abbott Company Information
13.10.2 Abbott Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.10.3 Abbott Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Abbott Main Business Overview
13.10.5 Abbott Latest Developments
13.11 Boehringer Ingelheim International
13.11.1 Boehringer Ingelheim International Company Information
13.11.2 Boehringer Ingelheim International Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.11.3 Boehringer Ingelheim International Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Boehringer Ingelheim International Main Business Overview
13.11.5 Boehringer Ingelheim International Latest Developments
13.12 Takeda Pharmaceutical
13.12.1 Takeda Pharmaceutical Company Information
13.12.2 Takeda Pharmaceutical Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.12.3 Takeda Pharmaceutical Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Takeda Pharmaceutical Main Business Overview
13.12.5 Takeda Pharmaceutical Latest Developments
13.13 Amicus Therapeutics
13.13.1 Amicus Therapeutics Company Information
13.13.2 Amicus Therapeutics Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.13.3 Amicus Therapeutics Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Amicus Therapeutics Main Business Overview
13.13.5 Amicus Therapeutics Latest Developments
13.14 Moderna
13.14.1 Moderna Company Information
13.14.2 Moderna Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.14.3 Moderna Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Moderna Main Business Overview
13.14.5 Moderna Latest Developments
13.15 Biomarin
13.15.1 Biomarin Company Information
13.15.2 Biomarin Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.15.3 Biomarin Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Biomarin Main Business Overview
13.15.5 Biomarin Latest Developments
13.16 JCR Pharmaceutical
13.16.1 JCR Pharmaceutical Company Information
13.16.2 JCR Pharmaceutical Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.16.3 JCR Pharmaceutical Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 JCR Pharmaceutical Main Business Overview
13.16.5 JCR Pharmaceutical Latest Developments
13.17 ISU ABXIS
13.17.1 ISU ABXIS Company Information
13.17.2 ISU ABXIS Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.17.3 ISU ABXIS Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 ISU ABXIS Main Business Overview
13.17.5 ISU ABXIS Latest Developments
13.18 Idorsia Pharmaceuticals
13.18.1 Idorsia Pharmaceuticals Company Information
13.18.2 Idorsia Pharmaceuticals Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.18.3 Idorsia Pharmaceuticals Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Idorsia Pharmaceuticals Main Business Overview
13.18.5 Idorsia Pharmaceuticals Latest Developments
13.19 AVROBIO
13.19.1 AVROBIO Company Information
13.19.2 AVROBIO Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.19.3 AVROBIO Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 AVROBIO Main Business Overview
13.19.5 AVROBIO Latest Developments
13.20 Resverlogix
13.20.1 Resverlogix Company Information
13.20.2 Resverlogix Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.20.3 Resverlogix Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Resverlogix Main Business Overview
13.20.5 Resverlogix Latest Developments
13.21 Chiesi Farmaceutici
13.21.1 Chiesi Farmaceutici Company Information
13.21.2 Chiesi Farmaceutici Lysosomal Storage Disorder Drugs Product Portfolios and Specifications
13.21.3 Chiesi Farmaceutici Lysosomal Storage Disorder Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Chiesi Farmaceutici Main Business Overview
13.21.5 Chiesi Farmaceutici Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.